Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olomorasib phase 1/2 study in KRAS G12C-mutant advanced solid tumors
jRCT2031210265Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2021
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of olomorasib in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), endometrial cancer (EC) and 3 more (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Recommended phase 2 dose of olomorasib monotherapy, Safety and tolerability of olomorasib alone or in combination and 3 more. Started Sep 2021; status: active, not recruiting.
02
Drugs
olomorasib
03
Conditions
non-small cell lung cancer (NSCLC)colorectal cancer (CRC)endometrial cancer (EC)ovarian cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on jRCT2031210265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210265.